Silence Therapeutics PLC (SLN) Stock Analysis

Silence Therapeutics PLC (SLN) is a publicly traded company in the HEALTHCARE sector. It trades at $6.37, carries a market capitalization of $308.44M. This page summarizes the public market data, fundamentals, and frequently asked questions for SLN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Silence Therapeutics PLC currently has a Neutral sentiment score of 0.08.

About Silence Therapeutics PLC

Silence Therapeutics PLC is a London-based biotechnology company specializing in the development of innovative ribonucleic acid (RNA) therapies aimed at addressing unmet medical needs in hematology, cardiovascular diseases, and various rare and metabolic disorders. By leveraging its proprietary RNAi technology platform, Silence is positioned to advance transformative therapeutics that target specific disease mechanisms, offering potentially groundbreaking treatments for patients. With a robus...

GNG Research Analysis

GNG Research scores Silence Therapeutics PLC (SLN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for SLN.

Frequently Asked Questions

Does SLN pay dividends?

Silence Therapeutics PLC (SLN) does not currently pay a regular dividend.

What is SLN's market cap?

Silence Therapeutics PLC (SLN) has a market capitalization of $308.44M with a current stock price of $6.37.